Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
October 26 2022 - 9:00AM
Business Wire
CEO Shawn Singh to lead discussion on the
future of mental health solutions
Vistagen (Nasdaq: VTGN), a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression, and
other central nervous system (CNS) disorders, today announced that
the company’s Chief Executive Officer, Shawn Singh, will lead a
Concordia Live Webinar on the need for innovative approaches to
mental health treatment. This virtual roundtable session will
explore how Americans can work together to break down mental health
stigmas, as well as the logistics of implementing a new standard of
care felt horizontally across a diverse, equitable society.
“Vistagen is holding a series of meetings with influential
leaders across the country to discuss the current challenges in our
nation’s mental health crisis and advance needed solutions,” said
Shawn Singh, Chief Executive Officer of Vistagen. “Although
communities are struggling to solve urgent mental health
challenges, sharing success stories and creating spaces for open
conversation can go a long way in achieving our shared goals. I am
excited for our discussion and look forward to sharing how the
emerging treatment landscape for anxiety and depression has the
potential to help patients live happier and more productive
lives.”
The impact of the COVID-19 pandemic on mental health and mental
health systems has been profound and will likely continue for many
years to come. The webinar will address how the United States can
implement practical solutions that prioritize mental and physical
health parity and improve mental health therapies, including
expanding access to treatment and diminishing stigma around seeking
care and resources amid our country’s growing mental health
crisis.
The webinar, “Addressing Stigmas and Solutions to Mental
Health Challenges,” is taking place on October 27th, 2022 at
12:00 PM Eastern Time. The speakers invited to participate in the
webinar include:
- Kana Enomoto – Director of Brain Health, McKinsey Health
Institute
- Malisa Aksentijevic – Founder and CEO, WEVO Group
- Dr. Zabina Bhasin – Founder, In KidZ
Registration information can be found
here.
The webinar is the third Concordia event focused on prioritizing
mental health and outlining strategies and recommendations to
address this growing crisis. It quickly follows last month’s
successful 2022 Concordia Summit, where Singh joined Founder of the
MindUP™ | The Goldie Hawn Foundation, as well as other preeminent
C-suite executives, politicians, nonprofit leaders, and
entrepreneurs in a roundtable entitled “The Importance of Mental
Health in a Social World.” Singh also hosted a fireside chat with
the U.S. Surgeon General, Vice Admiral Vivek H. Murthy, MD, MBA, at
the 2022 Concordia Americas Summit on how the public and private
sectors can work together to advance critical mental health care
initiatives.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused
biopharmaceutical company striving to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available.
Vistagen’s clinical-stage candidates are targeting multiple forms
of anxiety and depression. PH94B and PH10 belong to a new class of
drugs known as pherines, which are odorless and tasteless
investigational neuroactive steroids designed with a novel
rapid-onset mechanism of action that activates chemosensory neurons
in the nasal passages and can impact the olfactory-amygdala neural
circuits without systemic uptake or direct activity on CNS neurons
in the brain. Vistagen is passionate about transforming mental
health care and redefining what is possible in the treatment of
anxiety and depression. Connect at www.Vistagen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. These
forward-looking statements involve known and unknown risks that are
difficult to predict and include all matters that are not
historical facts. In some cases, you can identify forward-looking
statements by the use of words such as "may," "could," "expect,"
"project," "outlook," "strategy," "intend," "plan," "seek,"
"anticipate," "believe," "estimate," "predict," "potential,"
"strive," "goal," "continue," "likely," "will," "would" and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by Vistagen and its management,
are inherently uncertain. These risks are fully discussed in the
section entitled "Risk Factors" in the Company’s most recent Annual
Report on Form 10-K for the fiscal year ended March 31, 2022 and in
the Company’s most recent Quarterly Report on Form 10-Q for the
quarter ended June 30, 2022, as well as discussions of potential
risks, uncertainties, and other important factors in our other
filings with the U.S. Securities and Exchange Commission (SEC). The
Company’s SEC filings are available on the SEC’s website at
www.sec.gov. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release and should not be relied upon as representing the
Company’s views as of any subsequent date. The Company explicitly
disclaims any obligation to update any forward-looking statements,
other than as may be required by law. If the Company does update
one or more forward-looking statements, no inference should be made
that the Company will make additional updates with respect to those
or other forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026005459/en/
Investors: Mark Flather Vice President, Investor Relations (650)
577-3617 mflather@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024